|
WO2021011927A1
|
|
Complement inhibitor dosing regimens
|
|
WO2021007111A1
|
|
Viral vector therapy
|
|
AU2018386304A1
|
|
Dosing regimens and related compositions and methods
|
|
WO2019089653A1
|
|
Treatment of disorders
|
|
WO2018187813A1
|
|
Dosing regimens and related compositions and methods
|
|
AU2017346486A1
|
|
Combination therapy for C3 inhibition
|
|
AU2016253654A1
|
|
Injectable combination therapy for eye disorders
|
|
CN108431019A
|
|
Dosage regimen
|
|
US2016153985A1
|
|
Complement assays and uses thereof
|
|
US2017246298A1
|
|
Methods and compositions for cancer treatment and treatment selection
|
|
WO2014152391A1
|
|
Cell-penetrating compstatin analogs and uses thereof
|
|
CN105051057A
|
|
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
US2016194359A1
|
|
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
|
US2016067357A1
|
|
Detection of high risk drusen
|
|
WO2013070895A1
|
|
Systems and methods for assembling electronic medical records
|
|
AU2012272706A1
|
|
Methods of treating chronic disorders with complement inhibitors
|
|
CN103687867A
|
|
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
|
|
WO2012006599A2
|
|
Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
|
|
WO2011137422A2
|
|
Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
|
|
AU2008214359A1
|
|
Local complement inhibition for treatment of complement-mediated disorders
|
